Xcout Intel
ONCOPEPTIDES competitors & alternatives
The 12 closest competitors and alternatives to ONCOPEPTIDES among biotech companies — ranked by similarity to what ONCOPEPTIDES actually does, not by market-cap band.
Subscribe to see ONCOPEPTIDES’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ONCOPEPTIDES
Oncopeptides is a pharmaceutical company that develops targeted cancer therapies utilizing proprietary platforms like peptide drug conjugates. The company focuses on treating difficult-to-treat hematological diseases and rare cancers, such as multiple myeloma, aiming to provide new treatment options for patients with significant unmet medical needs.
ONCOPEPTIDES at a glance
ONCOPEPTIDES is a biotech company headquartered in United Kingdom. Xcout tracks 10 named people at ONCOPEPTIDES, including Sofia Heigis (Chief Executive Officer, CEO).
ONCOPEPTIDES leadership
- Sofia HeigisChief Executive Officer, CEO
- Eva NordströmChief Operating Officer (COO) and Deputy Managing Director
- Henrik BergentoftChief Financial Officer (CFO)
- Stefan NorinChief Medical Officer (CMO)
- Per Wold-OlsenChairman
- Lotta LarssonHead of Human Resources
4 more named people on record for ONCOPEPTIDES, with roles, board committees and tenure — see the full roster →
Top 12 ONCOPEPTIDES competitors
Ranked by semantic similarity — how close each company is to ONCOPEPTIDES by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that develops targeted, bespoke molecules using peptide engineering and iterative design to treat cancer patients with precision. The company advances a portfolio of radiotherapeutics utilizing optimized binders, linkers, chelators, and radioisotopes for solid tumors.
Biotechnology
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Similar biotech company
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Biotechnology
Cybrexa Therapeutics is a clinical-stage oncology biotechnology company that develops tumor-targeting peptide-drug conjugates (PDCs) for cancer patients. Its proprietary alphalex technology uses a pH-driven approach for antigen-independent, intracellular delivery of anti-cancer agents directly to tumors and metastases.
Similar biotech company
Active Biotech is a biotechnology company that develops pharmaceutical treatments for cancer and inflammatory eye diseases, focusing on specialist indications such as hematological cancers, solid tumors, and non-infectious uveitis. Its clinical pipeline includes immunomodulating molecules and antibody-based therapies like tasquinimod, laquinimod, and naptumomab.
Biotechnology
Opna Bio is a clinical-stage biopharmaceutical company that discovers and develops novel oncology therapeutics targeting key regulators of cancer. Its pipeline includes epigenetic inhibitors such as OPN-6602 for multiple myeloma and zavabresib for myelofibrosis.
Similar biotech company
Oncodesign Precision Medicine is a biopharmaceutical company that develops innovative therapeutic and diagnostic solutions targeting treatment resistance, metastasis, and diseases such as oncology, inflammatory bowel disease, and Parkinson's disease. Utilizing proprietary technologies like OncoSNIPER, Nanocyclix, and PROMETHE, the company advances first-in-class and best-in-class precision medicine programs to serve patients, clinicians, and pharmaceutical partners.
Biotechnology
IGF Oncology, LLC develops targeted cancer therapeutics designed to provide higher efficacy and lower side effects compared to traditional chemotherapy drugs. Its lead product, IGF-MTX, combines methotrexate with a targeting protein and has advanced through clinical trials for solid tumors and myelodysplastic syndrome (MDS).
Biotechnology
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Biotechnology
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Biotechnology
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
Biotechnology
Parabilis Medicines is a biopharmaceutical company that develops ultra-tunable peptide therapeutics utilizing its proprietary Helicon platform. The company focuses on creating novel medicines to target historically undruggable conditions, primarily addressing cancer and other serious diseases with critical medical needs.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ONCOPEPTIDES and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ONCOPEPTIDESand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →